- English (USA)
- English (UK)
- English (India)
- English (Australia)
- English (South Africa)
- English (Philippines)
- English (Nigeria)
- Deutsch
- Español (España)
- Español (México)
- Français
- Italiano
- Nederlands
- Polski
- Português (Portugal)
- Português (Brasil)
- Русский
- Türkçe
- العربية
- Ελληνικά
- Svenska
- Suomi
- עברית
- 日本語
- 한국어
- 简体中文
- 繁體中文
- Bahasa Indonesia
- Bahasa Melayu
- ไทย
- Tiếng Việt
- हिंदी
Barinthus Biotherapeutics PLC (BRNS)
Barinthus Biotherapeutics PLC stock price live, this page displays NASDAQ BRNS stock exchange data. View the BRNS premarket stock price ahead of the market session or assess the after hours quote. Monitor the latest movements within the Barinthus Biotherapeutics PLC real time stock price chart below.
What Is the Barinthus Biotherapeutics PLC Stock Price Today?
The Barinthus Biotherapeutics PLC stock price today is 0.728.
What Is the Stock Symbol for Barinthus Biotherapeutics PLC?
The stock symbol for Barinthus Biotherapeutics PLC is "BRNS."
What Stock Exchange Does Barinthus Biotherapeutics PLC Trade On?
Barinthus Biotherapeutics PLC is listed and trades on the NASDAQ stock exchange.
Is Barinthus Biotherapeutics PLC a Good Stock to Buy?
Determining whether Barinthus Biotherapeutics PLC—or any stock—is a good buy requires comprehensive analysis. To evaluate its potential, users can sign up to InvestingPro, where they can assess stock price fair value and other essential metrics.
You can find more details by visiting the additional pages to view historical data, charts, latest news, analysis or visit the forum to view opinions on the BRNS quote. (ISIN: US91864C1071)
What Is the Barinthus Biotherapeutics PLC Stock Price Today?
The Barinthus Biotherapeutics PLC stock price today is 0.728.
What Is the Stock Symbol for Barinthus Biotherapeutics PLC?
The stock symbol for Barinthus Biotherapeutics PLC is "BRNS."
What Stock Exchange Does Barinthus Biotherapeutics PLC Trade On?
Barinthus Biotherapeutics PLC is listed and trades on the NASDAQ stock exchange.
Is Barinthus Biotherapeutics PLC a Good Stock to Buy?
Determining whether Barinthus Biotherapeutics PLC—or any stock—is a good buy requires comprehensive analysis. To evaluate its potential, users can sign up to InvestingPro, where they can assess stock price fair value and other essential metrics.
You can find more details by visiting the additional pages to view historical data, charts, latest news, analysis or visit the forum to view opinions on the BRNS quote. (ISIN: US91864C1071)
NASDAQ
Currency in USD
0.728
+0.018(+2.54%)
Closed·
Fair Value
An estimate of a stock's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Day's Range
0.710
0.745
52 wk Range
0.640
2.920
BRNS is not included in our AI-picked strategies. See which stocks are.
Fair Value
An estimate of a stock's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Day's Range
0.7100.745
52 wk Range
0.6402.920
Key Statistics
Edit
Prev. Close
Open
Volume
Average Volume (3m)
1-Year Change
Book Value / Share
Fair Value
UnlockFair Value Upside
UnlockMarket Cap
Shares Outstanding
Revenue
Net Income
EPS
EPS Growth Forecast
UnlockNext Earnings Date
N/A
(N/A)
Dividends Payment Streak
UnlockP/E Ratio
Return on Assets
Return on Equity
Gross Profit Margin
Price/Book
EBITDA
EV/EBITDA
Beta
Prev. Close
Open
Volume
Average Volume (3m)
1-Year Change
Book Value / Share
Fair Value
UnlockFair Value Upside
UnlockMarket Cap
Shares Outstanding
Revenue
Net Income
EPS
EPS Growth Forecast
UnlockNext Earnings Date
N/A
(N/A)
Dividends Payment Streak
UnlockP/E Ratio
Return on Assets
Return on Equity
Gross Profit Margin
Price/Book
EBITDA
EV/EBITDA
Beta
BRNS Scorecard
Company’s Health
Assesses a company's financial position by analyzing its market value, financial ratios, industry benchmarks, and competitors.
UnlockFair Value
An estimate of a stock's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Unlock PriceAnalysts Sentiment
Strong Buy
Price Target
5.500
Upside
+655.49%
Members' Sentiments
Bearish
Bullish
ProTips
Tips that distill complex financial data into concise, actionable investment insights.
Quickly burning through cash
- Vaccitech ADR receives Investment Bank Analyst Rating Update
- Investing.com
Pro - Vaccitech ADR receives Investment Bank Analyst Rating Update
- Investing.com
Pro
- Vaccitech ADR receives Investment Bank Analyst Rating Update
- Investing.com
Pro
Technical Analysis
Summary
Strong Sell
Sell
Neutral
Buy
Strong Buy
Strong Buy
Technical Indicators
Buy
Moving Averages
Strong Buy
Barinthus Biotherapeutics PLC Company Profile
Barinthus Biotherapeutics plc, a clinical-stage biopharmaceutical company, focuses on developing immunotherapeutic drug candidates for treating auto-immune and inflammatory diseases. Its lead candidate is VTP-1000, which is in Phase 1 clinical trial to restore immune non-responsiveness to gluten in patients with celiac disease. The company is also developing VTP-300, an immunotherapeutic targeting chronic hepatitis B virus infection; VTP-200, a potential non-invasive treatment for persistent high-risk human papillomavirus; VTP-850, an immunotherapeutic candidate for prostate cancer; VTP-600, an immunotherapeutic candidate targeting MAGE-A3 and NY-ESO1 antigens; VTP-500, a prophylactic vaccine candidate to prevent middle east respiratory syndrome; VTP-400, a prophylactic vaccine candidate for shingles; and Vaxzevria, a prophylactic vaccine for the prevention of COVID-19 infection. The company was formerly known as Vaccitech plc and changed its name to Barinthus Biotherapeutics plc in November 2023. Barinthus Biotherapeutics plc was founded in 2016 and is headquartered in Didcot, the United Kingdom.
Barinthus Biotherapeutics PLC SWOT Analysis
HBV Breakthrough | BRNS sharpens focus on Hepatitis B Virus treatments, positioning itself to address a significant unmet medical need in a competitive landscape |
Financial Challenges | Negative EPS forecasts and recent workforce reduction highlight BRNS's struggle for profitability, with cash runway extended to Q2 2026 |
Strategic Pivot | Explore BRNS's agile response to market trends, prioritizing HBV and Celiac disease research while streamlining operations |
Market Potential | Analyst price targets range from $3 to $7, reflecting varied outlooks on BRNS's ability to capitalize on its focused pipeline and industry trends |
Compare BRNS to Peers and Sector
Metrics to compare | BRNS | Sector Sector - Average of metrics from a broad group of related Healthcare sector companies | Relationship RelationshipBRNSPeersSector | |
|---|---|---|---|---|
P/E Ratio | −0.4x | −2.0x | −0.6x | |
PEG Ratio | 0.01 | 0.19 | 0.00 | |
Price/Book | 0.4x | 2.7x | 2.6x | |
Price / LTM Sales | - | 17.7x | 3.4x | |
Upside (Analyst Target) | - | 197.8% | 42.5% | |
Fair Value Upside | Unlock | 11.4% | 5.8% | Unlock |
Analyst Ratings
2 Buy
0 Hold
0 Sell
Ratings:
2 analysts
Overall Consensus
Strong Buy
Analysts 12-Month Price Target:
Average 5.500
(+655.49% Upside)
Earnings
Latest Release
Nov 07, 2025
EPS / Forecast
-0.36 / -0.40
Revenue / Forecast
-- / --
People Also Watch
FAQ
What Is the Barinthus Biotherapeutics (BRNS) Stock Price Today?
The Barinthus Biotherapeutics stock price today is 0.728
What Stock Exchange Does Barinthus Biotherapeutics Trade On?
Barinthus Biotherapeutics is listed and trades on the Nasdaq Stock Exchange stock exchange.
What Is the Stock Symbol for Barinthus Biotherapeutics?
The stock symbol for Barinthus Biotherapeutics is "BRNS."
What Is the Barinthus Biotherapeutics Market Cap?
As of today, Barinthus Biotherapeutics market cap is 28.99M.
What Is Barinthus Biotherapeutics's Earnings Per Share (TTM)?
The Barinthus Biotherapeutics EPS (TTM) is -1.88.
When Is the Next Barinthus Biotherapeutics Earnings Date?
Barinthus Biotherapeutics will release its next earnings report on Mar 20, 2026.
From a Technical Analysis Perspective, Is BRNS a Buy or Sell?
Based on moving averages and other technical indicators, the daily buy/sell signal is Sell.
How Many Times Has Barinthus Biotherapeutics Stock Split?
Barinthus Biotherapeutics has split 0 times.
How Many Employees Does Barinthus Biotherapeutics Have?
Barinthus Biotherapeutics has 105 employees.
What is the current trading status of Barinthus Biotherapeutics (BRNS)?
As of Jan 23, 2026, Barinthus Biotherapeutics (BRNS) is trading at a price of 0.728, with a previous close of 0.710. The stock has fluctuated within a day range of 0.710 to 0.745, while its 52-week range spans from 0.640 to 2.920.
What Is Barinthus Biotherapeutics (BRNS) Price Target According to Analysts?
The average 12-month price target for Barinthus Biotherapeutics is USD5.500, with a high estimate of USD7 and a low estimate of USD4. 2 analysts recommend buying the stock, while 0 suggest selling, leading to an overall rating of Strong Buy. The stock has an +655.49% Upside potential.
Install Our App
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2026 - Fusion Media Limited. All Rights Reserved.